Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company’s medical legacy. Horizon's best-selling drug is Tepezza.
Graviton Biopharmaceutical Holdings Chairman and CEO Sam Waksal discusses growth investment opportunities in biotech and how the sector should be a national priority.
California-based Amgen will pay $116.50 in cash for each share of Horizon, which makes 12 marketed medicines and has a pipeline of more than 20 development programs.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amgen to buy Horizon Therapeutics in $26.4B dealAmgen is spending more than $26 billion to dive deeper into rare disease treatments with the acquisition of drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a treatment for thyroid eye disease that generated more than $1 billion in its first full year on the market.
Read more »
Amgen set to buy biotech firm Horizon at $26 bln valuation - Bloomberg NewsAmgen Inc is set to buy biotech firm Horizon Therapeutics Plc at a valuation of about $26 billion in what would be its largest acquisition, Bloomberg News reported on Monday.
Read more »
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billionAmgen Inc. undefined said Monday it has agreed to acquire Horizon Therapeutics Plc undefined in an all-cash deal valued at $27.8 billion, confirming earlier...
Read more »
Amgen Agrees to Deal to Buy Horizon TherapeuticsThe U.S. biotech company agreed to buy drugmaker Horizon Therapeutics in a deal valued at $27.8 billion, marking the largest healthcare merger of the year.
Read more »
Amgen to buy Horizon Therapeutics in $26.4 billion dealAmgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare autoimmune diseases, in a deal valued at $26.4 billion.
Read more »
WSJ News Exclusive | Amgen in Advanced Talks to Buy Horizon TherapeuticsAmgen is in advanced talks to buy drugmaker Horizon Therapeutics, people familiar with the matter say, in a deal likely to be valued at well over $20 billion
Read more »